The Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK has granted a temporary authorization for emergency use for Pfizer and BioNTech's mRNA vaccine (BNT162b2), against COVID-19.
A neuroprotective drug which is already in development may be particularly effective for MND patients carrying a newly discovered genetic risk factor, helping to halt progression or even prevent the onset of the devastating degenerative disease.
Pfizer/BioNTech and Moderna have each submitted formal applications for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA) for their COVID-19 vaccines: completing the rolling review process.
US based scientists have hit upon a method to efficiently identify potential biological mechanisms underlying autism spectrum disorder (ASD); the Harvard and MIT based researchers say the approach is an important first step toward developing treatments...